Christopher Hutchinson, MD
Obstetrics & Gynecology · West Columbia, SCNPI 1083662357
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2022 at $4,807 and has fallen 90.6% since, to $453 in 2025. Among obstetrics & gynecology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $36.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Pfizer$240
- Astellas Pharma US Inc$197
- Aspira Women's Health Inc$183
- Duchesnay USA Incorporated$177
- Bayer$136
- plus $1K from 34 others
What the payments were for
- Speaking & faculty fees$3,75051%
- Food & beverage$3,46747%
- Education$1031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $5,017 |
| Pfizer | 15 | $240 |
| Astellas Pharma US Inc | 11 | $197 |
| Aspira Women's Health Inc | 2 | $183 |
| Duchesnay USA Incorporated | 15 | $177 |
| Bayer | 8 | $136 |
| Exeltis, USA Inc. | 7 | $117 |
| Daiichi Sankyo Inc. | 5 | $107 |
| Sumitomo Pharma America, Inc. | 6 | $106 |
| Intuitive Surgical | 1 | $98 |
| Novo Nordisk | 5 | $93 |
| Baxter Healthcare | 1 | $71 |
| Sage Therapeutics, LLC | 4 | $70 |
| Therapeuticsmd, Inc. | 4 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Lupin Inc. | 4 | $58 |
| AMAG Pharmaceuticals, Inc. | 4 | $51 |
| Exact Sciences | 3 | $50 |
| Coopersurgical, Inc. | 3 | $41 |
| Mayne Pharma Commercial LLC | 2 | $40 |
| Galderma Laboratories, L.p. | 3 | $38 |
| Organon | 3 | $36 |
| Shield Therapeutics Inc | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Mylan Pharmaceuticals Inc. | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Amgen | 1 | $17 |
| Biogen | 1 | $17 |
| Seagen Inc. | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Millicent US Inc | 1 | $14 |
| Scynexis, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
| Avion Pharmaceuticals | 1 | $11 |
| Meditrina | 1 | $11 |
| Coloplast | 1 | $11 |
| Channel Medsystems, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OVA1$163
How this compares
$7,320 in reported general payments places this provider in the 90th percentile of 673 obstetrics & gynecology providers in South Carolina.
See all obstetrics & gynecology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $8,343 |
| PremarinEstrogens, Conjugated | 19 | $5,221 |
| Estradiol | 48 | $3,195 |
| Estradiol (Twice Weekly)Estradiol | 11 | $1,650 |
| DottiEstradiol | 22 | $1,534 |
| ValacyclovirValacyclovir Hcl | 22 | $435 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $247 |
| Alendronate Sodium | 17 | $114 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $113 |
| Fluconazole | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $197 | $8,34311 claims |
| PfizerPremarin | $240 | $5,22119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 673 obstetrics & gynecology providers in South Carolina.
Other obstetrics & gynecology in West Columbia
- Brooke NaffzigerWest Columbia$70K
- Janice BaconWest Columbia$9K
- Alvin StrasburgerWest Columbia$7K
- Christopher JenningsAnderson$1.3M
- William ColemanGreenville$242K
- Melvin SeidMauldin$235K
- Judith BurgisColumbia$59K
- Charis ChambersGreenville$46K
- Angela ChoiCharleston$43K
- Andrew FuttermanCharleston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.